Key Data Elements
Demographics
Molecular Markers
KRAS Status
BRAF Status
Performance Status
VEGF Inhibitors
TKI Inhibitors
Immunotherapy
Stage at Diagnosis
Metastatic
Lines of Therapy
Survival & Outcomes
About Qdata® Colorectal Cancer
Colorectal cancer is a disease where cells in the colon (large intestine) or rectum grow uncontrollably. It is usually highly treatable and often preventable when detected early through routine screening.
Colorectal cancer medical research is aided by deeply abstracted, longitudinal colorectal cancer patient records that capture clinical detail required to understand disease biology, molecular subtype, and treatment response. The dataset includes KRAS and BRAF mutation status, VEGF inhibitor and immunotherapy exposure, stage at diagnosis, and detailed multi-line treatment sequencing. Each record is curated under oncology oversight and structured to support regulatory and development use.
The colorectal cancer dataset maintains high completeness across the clinical variables that drive decision-making, including molecular subtype, performance status, stage at diagnosis, and documented outcomes.
Evidence in Action
Comprehensive Coverage Across the Full Colorectal Cancer Continuum
With 91% of metastatic patients with outcome data, 74% of patients with performance status, and 4.5 years average length of follow-up, the dataset reflects both the specialized care setting and the surgical complexity central to colorectal cancer management.
Comprehensive Coverage of Colorectal Cancer Treatment Modalities
The colorectal cancer dataset reflects the full treatment landscape, from frontline chemotherapy combinations through VEGF inhibitors, TKI inhibitors, and immunotherapy in later-line and biomarker-selected settings. Each line of therapy is documented in sequence, with detailed response and outcome capture across colon and rectal primary sites.
Actionable Biomarker Data for Targeted Therapy Research
The colorectal cancer dataset captures clinically actionable mutation status at the individual patient level through structured abstraction of molecular pathology results. KRAS and BRAF mutation status are documented to support subgroup analyses, treatment eligibility research, and targeted therapy evidence generation across metastatic and earlier-stage settings.
KRAS Mutated
BRAF Mutated
Custom Data Curation
Need data tailored to your exact study design requirements?
Our purpose-built, fit-for-purpose datasets are designed to support rigorous research and confident decision-making. These datasets can be tailored
around custom inclusion and exclusion criteria, in addition to including all standard abstracted data elements.
Ready to Explore the Colorectal Cancer Dataset?
Connect with our team to discuss your research objectives and receive a tailored data overview.